APA (7th ed.) Citation

M, D., C, C., V, G., S, R., F, M., F, G., . . . E, R. (2026). Posterior Reversible Encephalopathy Syndrome with Angiogenesis Inhibitors for Solid Tumours: Clues from a Disproportionality Analysis of the FDA Adverse Event Reporting System and Pharmacodynamics. Targeted oncology, 21(3), 433. https://doi.org/10.1007/s11523-026-01222-3

Chicago Style (17th ed.) Citation

M, Donati, Cancellerini C, Giunchi V, Rossi S, Massari F, Gelsomino F, Poluzzi E, and Raschi E. "Posterior Reversible Encephalopathy Syndrome with Angiogenesis Inhibitors for Solid Tumours: Clues from a Disproportionality Analysis of the FDA Adverse Event Reporting System and Pharmacodynamics." Targeted Oncology 21, no. 3 (2026): 433. https://doi.org/10.1007/s11523-026-01222-3.

MLA (9th ed.) Citation

M, Donati, et al. "Posterior Reversible Encephalopathy Syndrome with Angiogenesis Inhibitors for Solid Tumours: Clues from a Disproportionality Analysis of the FDA Adverse Event Reporting System and Pharmacodynamics." Targeted Oncology, vol. 21, no. 3, 2026, p. 433, https://doi.org/10.1007/s11523-026-01222-3.